Safety Notices

From time to time notices relating to the safety and/or quality of medicinal products are published by the Health Products Regulatory Authority

These notices are classified under several priority related categories and may relate to human and veterinary medicines, or medical devices.   

The issues covered by these notices will range from quality defect information and medicinal product safety information through to updated information on the appropriate usage of medicines or devices.

Notices are categorised in accordance with their importance at time of publication.

The four notice categories are outlined as follows:

  • Advisory  -  Routine safety information            
  • Warning  -  Urgent safety information
  • Recall  -  Urgent safety information relating to a product recall
  • Publications  -  General safety information provided by the HPRA for publication via 3rd parties e.g. MIMS

The HPRA Drug Safety Newsletter is also published on a regular basis.

Date Title Type
17/07/2018 Keytruda (pembrolizumab) - Important Safety Information from Merck Sharp & Dohme B.V. as approved by the HPRA 3rd Party Publications
13/07/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 3rd Party Publications
10/07/2018 Tecentriq (atezolizumab) - Important Safety Information Notice from Roche Products (Ireland) Ltd. as approved by the HPRA 3rd Party Publications
05/07/2018 Recall of a number of Valsartan-containing film coated tablet products - Important information for patients and healthcare professionals Recall
04/07/2018 Emerade Range of treatments for Acute Allergic Reactions – Important Information for Users and Healthcare Professionals Advisory
02/07/2018 Summary of Direct Healthcare Professional Communications (DHPCs) issued in June 2018 3rd Party Publications
25/06/2018 Darunavir/cobicistat - Important Safety Information from Janssen as approved by the HPRA 3rd Party Publications
06/06/2018 Vectibix (panitumumab) - Important Safety Information from Amgen as approved by the HPRA 3rd Party Publications
05/06/2018 Summary of Direct Healthcare Professional Communications (DHPCs) issued in May 2018 3rd Party Publications
28/05/2018 Granulocyte colony-stimulating factors (G-CSFs) (Filgrastim, Lenograstim, Lipegfilgrastim and Pegfilgrastim) - Important Safety Information from Amgen Europe B.V, Chugai Pharma UK, Teva, Apotex Europe B.V, and Accord Healthcare Ltd as approved by the HPRA 3rd Party Publications